'Relief to poor': MNC patent on costly TB drug rejected, to 'help' generic production

By A Representative
On March 23, 2023, the Indian Patent Office (IPO) rejected pharma company Janssen’s application for an extension of its patent on bedaquiline, a drug used in the treatment of tuberculosis patients. The verdict that came just a day ahead of World Tuberculosis Day was celebrated by health activists and tuberculosis survivors in India.
Janssen, owned by multinational Johnson and Johnson, applied for an extension of their original patent on bedaquiline on the basis of having discovered a new formulation. According to Indian law, in order to be granted a patent extension in such a situation, the manufacturer has to show that the new formulation leads to an enhanced therapeutic effect. Janssen repeatedly failed to prove that in the case of bedaquiline salt formulation.
If the patent on bedaquiline had been extended, public and family budgets would have remained burdened by unjustifiable high costs of the drug. Bedaquiline is an important drug for TB patients on many counts. The older TB drugs include injectables such as kanamycin, which have severe side effects including permanent hearing loss. On the other hand, bedaquiline is an oral drug with much higher safety and efficacy profile.

Bedaquiline was the first new tuberculosis drug in forty years when it was approved by the US Food and Drug Administration in 2012. According to the most recent Global Tuberculosis Report, in 2021, India recorded 119,000 cases of multidrug resistant tuberculosis and over half a million deaths caused by the disease.
Priyam Lizmary Cherian, an intellectual property lawyer who argued the case at the IPO, said that the decision should ease the generic production of bedaquiline, making safe and effective treatment more accessible. “India, being a generic production hub, can count on companies being able to pick up production after the original patent expires in July 2023,” she said.
Widely recognized as a disease of the poor, tuberculosis is generally not a prominent field in Big Pharma research and development, although it affects the lives of hundreds of thousands in the Global South. In 2021, the money invested in this field globally was not even half of what a UN High Level Meeting identified as a target.
---
Source: Peoples Dispatch / Globetrotter News Service

A fearless spirit lost: Rebecca Thomson dies at 17-hour Catalina Swim Mark

By Harsh Thakor On July 26, 2026, Rebecca “Becky” Thomson suffered cardiac arrest while attempting the Catalina Channel Swim — a marathon open water crossing from Catalina Island to the California mainland. After swimming for 17 hours, Thomson collapsed in the water. Despite the painstaking efforts of emergency responders and the medical staff at Harbor-UCLA Medical Center, she succumbed to a devastating hypoxic brain injury and died Friday evening.

Hyderabad-based Urdu university "bars" entry of its new chancellor, who had "initiated" reforms in institute

Counterview Desk In an unusual controversy, Aslam Parvaiz, vice-chancellor of of the Hyderabad-based Maulana Azad National Urdu University (MANUU) has restricted the entry of its newly appointed Chancellor, Firoz Bakht Ahmed, allegedly because he was trying to initiate reforms, including setting up of a Maulana Azad Center for Composite Culture and Progressive Studies, Model Madrasa, Center for Empowerment of Muslim Women, Course for the Development of Legal Vocabulary and Legal Consciousness in Urdu, and so on.

Did the Sabarmati riverfront make Ahmedabad more vulnerable?

By Rajiv Shah Currently living in Los Angeles, I find myself missing Ahmedabad . Not because I miss living through the city's recent devastating floods—which, experts say, resulted from a combination of extreme meteorological events and chronic urban infrastructure bottlenecks—but because I am unable to make an on-the-spot assessment of the disaster.

Counterview

Search This Blog